Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.
The poster presentations will feature data from the Company's proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform.
Details for Avacta's poster presentations are below and can be found on the AACR website:
Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage
Session Category: Experimental and Molecular Therapeutics
Session Title: Therapeutic Approach to Attack the Tumor Microenvironment
Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights
Session Category: Tumor Biology
Session Title: Targeting the Tumor Microenvironment: A Brave New World
Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
Abstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates
Session Title: First-in-Human Phase I Clinical Trials 2
Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CT
For further information from Avacta, please contact:
Avacta Group plcMichael Vinegrad, Group CommunicationsDirector
www.avacta.com
Peel Hunt (Nomad and Broker)James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers
www.panmureliberum.com
ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
avacta@icrhealthcare.com
Investor ContactRenee Leck THRUST Strategic Communications
renee@thrustsc.com
Media ContactCarly ScadutoCarly Scaduto Consulting
Carly@carlyscadutoconsulting.com
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Belgium's Sotrad Water Honoured With Global Award in Dubai for Solar-powered Drinking Water Innovation
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Sotrad Water Srl from Belgium has been named the second runner-up in the Innovative Projects Award (Large Projects category) during the fourth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award for its Pump&Drink® Hydro1000 initiative, a solar-powered water treatment and distribution solution designed to serve rural communities in Africa and beyond. Held under the Mohammed bin Rashid Al Maktoum Global Initiatives and supervised by the UAE Water Aid Foundation (Suqia UAE), the award celebrates innovative technologies that address global water scarcity using renewable energy. It offers a total prize pool of USD 1 million and supports scalable, sustainable impact. Sotrad Water's Pump&Drink® system is a self-contained, solar-powered solution that pumps, treats, stores and distributes water from boreholes. The system is already operational in 22 countries, with over 500 units installed, including 150 in the Ivory Coast during a successful pilot phase in 2020. A full-scale rollout is now under way through 2025. Each station includes a submersible pump powered by a solar array of eight modules, as well as advanced filtration (50-130 microns) and proportional chlorination for disinfection. Treated water is stored in elevated 8,000-litre tanks, then distributed via gravity-fed taps to serve surrounding communities. The systems do not require a full-time technician and feature remote monitoring capabilities using SMS-based data transmission for real-time performance tracking. The technology has earned the 'Efficient Solution' label from the Solar Impulse Foundation for its sustainable impact. Each station can produce between 10 and 30 cubic metres of clean water per day, depending on local water quality and needs. The EUR 49 million rollout includes 1,150 stations and is supported by regional water committees to ensure ongoing maintenance and local community engagement. 'Solving the global water crisis requires collaboration. We cannot work in solitude or design solutions limited to one location. We must address all water uses, including agriculture, drinking water, wastewater and even cooling in data centres, together. This award acknowledges 15 years of hard work and supports our vision to expand technology transfer. It brings global innovations under one roof, which is a true reflection of Dubai's spirit. It inspires hope for a future free from water scarcity,' said Raoul Antoine, General Manager of Sotrad Water.
Business Upturn
3 hours ago
- Business Upturn
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age. This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for persons 12 years of age and older in the US, EU and United Kingdom under the trade name VIMKUNYA®. The global, randomized, double-blind, placebo-controlled study (NCT07003984), sponsored by Bavarian Nordic, will evaluate the safety and immunogenicity of CHIK VLP vaccine in 720 children 2 to 11 years of age for two years. Primary results from the study are anticipated in the first half of 2028. Paul Chaplin, President & CEO of Bavarian Nordic, said: 'Upon the successful approvals earlier this year of our chikungunya vaccine for persons aged 12 and older, we are pleased to initiate this Phase 3 study in children for whom there are currently no vaccines available to prevent against chikungunya. This study represents a significant part of our commitment to the further development of the vaccine to help ensure access for people of all ages.' About VIMKUNYA® Chikungunya vaccine (recombinant, adsorbed) VIMKUNYA (CHIKV VLP) is the first and only virus-like particle (VLP) vaccine for the prevention of chikungunya disease in individuals aged 12 years and above. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. VIMKUNYA is the only single-dose vaccine against chikungunya disease available in a prefilled syringe. VIMKUNYA does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 20251,2 and the United Kingdom in May 20253. The US, EU and UK approvals of VIMKUNYA (CHIKV VLP vaccine) were all based on results from two phase 3 clinical trials which enrolled more than 3,500 healthy individuals 12 years of age and older. The studies met their primary endpoints, with results showing that 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8% of the vaccinated individuals, (97.8% in individuals 12 years to 64 and 87.3% in over 65-year-olds). The key secondary endpoint of seroresponse rate at day 8 post vaccination was 46.6% and 96.8% at day 15 in the 12–64-year-old population and 82.3% at day 15 for the over 65 population. The vaccine was well-tolerated and vaccine-related adverse events were mainly mild or moderate in nature. The most common side effects were pain at the injection site, fatigue, headache, and muscle pain4,5. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV). In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, CHIKV has been identified in more than 110 countries, with evidence of transmission confirmed in more than 50 countries over the past five years6. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover within 1-2 weeks, but 30-40% of those affected may develop chronic arthritis that can last for months or even years7. In 2024, 620,000 cases of chikungunya and over 200 deaths were reported worldwide8. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile9. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Rolf Sass Sørensen, Vice President Investor Relations, [email protected], Tel: +45 61 77 47 43 US: Graham Morrell, Paddock Circle Advisors, [email protected], Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03 1 Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older. 2 Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older. 3 Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom. 4 Richardson JS, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults. medRxiv 2024.10.11.24315179. 5 Tindale LC, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥65 Years of Age. medRxiv 2024.10.10.24315205. 6 Centers for Disease Control and Prevention. Areas at Risk for Chikungunya. 7 European Centre for Disease Prevention and Control. Chikungunya virus disease. 8 European Centre for Disease Prevention and Control. Chikungunya virus disease case notification rate per 100 000 population, January 2024-December 2024. 9 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/ PMID: 38711542; PMCID: PMC11070701. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
3 hours ago
- Yahoo
Skanska signs contract amendment for airport expansion in Redmond, Oregon, USA for USD 98M, about SEK 1.0 billion
STOCKHOLM, June 12, 2025 /PRNewswire/ -- Skanska has signed a contract amendment with the City of Redmond for the Redmond Municipal Airport Expansion Project in Redmond, Oregon, USA. The contract amendment is worth USD 98M, about SEK 1.0 billion, which will be included in the US order bookings for the second quarter of 2025. The project includes over 7,400 square meters (80,000-SF) of concourse expansion and a terminal renovation. The project includes new gates with jet bridges, new retail, and concessions. The expansion includes mass timber roof structure features and will accommodate capacity demands, improve ADA accessibility, increase energy efficiency, and enhance the passenger experience. Work will begin in June 2025 and is expected to be completed in January 2028. For further information please contact:Daniela Arellano, Communications Director, Skanska USA, tel +1 -213-317-4977Andreas Joons, Press Officer, Skanska Group, tel +46 (0)10 449 04 94Direct line for media, tel +46 (0)10 448 88 99 This and previous releases can also be found at This information was brought to you by Cision The following files are available for download: 20250612 US Redmond Airport ENG Image 1 - Redmont Airport - image cred RS&H Image 2 - Redmont Airport - image cred RS&H View original content: SOURCE Skanska
